Basisstatistiken
| CIK | 102198 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Calmare Therapeutics Inc
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| July 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SECURITIES EXCHANGE ACT OF 1934 Release No. 97911 / July 14, 2023 Admin. Proc. File No. 3-20550 In the Matter of CALMARE THERAPEUTICS INCORPORATED OPINION OF THE COMMISSION SECTION 12(j) PROCEEDING Grounds for Remedial Action Failure to Comply with Periodic Filing Requirements Company failed to file periodic reports in violation of Section 13(a) |
|
| June 9, 2020 |
Entry into a Material Definitive Agreement, Other Events 8-K 1 ea122850-8kcalmaretherap.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2020 (June 1, 2020) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 |
|
| June 9, 2020 |
Exhibit 10.1 P.O. Box 76, Building 37 1st Avenue, North of Cermak Road, Hines, IL 60141 www.fss.va.gov In Reply Refer To: 003B6B 06/01/2020 Conrad Mir, President & CEO Calmare Therapeutics Incorporated 1375 Kings Hwy, STE 400 Fairfield, CT, 06824 -5380 RE: Department of Veterans Affairs - Federal Supply Schedule: Contract Award Dear Mr. Mir: Congratulations! Enclosed is your Federal Supply Schedul |
|
| June 9, 2020 |
Exhibit 99.1 COMPANY NEWS FOR IMMEDIATE RELEASE CALMARE THERAPEUTICS AWARDED $2.5 MILLION, FIVE-YEAR CONTRACT BY U.S. DEPARTMENT OF VETERAN AFFAIRS FOR CALMARE® PAIN THERAPY DEVICES Contract No.: 36F797-20D0118 | Contract Term: Five Years Fairfield, CT – June 8, 2020 – Calmare Therapeutics Incorporated, (OTC: CTTC), the pain mitigation company, was awarded a five-year, $2.5 million Federal Supply |
|
| February 11, 2020 |
CTTC / Calmare Therapeutics Inc. / BARD ASSOCIATES INC - CALMARE THERAPEUTICS Passive Investment SC 13G/A 1 r13g123119cttc.txt CALMARE THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Calmare Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 5, 2019 |
8-K 1 f8k103019calmare.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2019 (October 30, 2019) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 |
|
| July 19, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 19, 2019 (July 12, 2019) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File Nu |
|
| June 12, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2019 (June 5, 2019) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File Num |
|
| June 10, 2019 |
8-K 1 f8k060419calmaretherape.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2019 (June 4, 2019) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 |
|
| June 3, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2019 (May 28, 2019) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File Numb |
|
| March 25, 2019 |
CALMARE THERAPEUTICS RECEIVES TWO FAVORABLE RULINGS IN DELAWARE CHANCERY COURT Exhibit 99.1 FOR IMMEDIATE RELEASE CALMARE THERAPEUTICS RECEIVES TWO FAVORABLE RULINGS IN DELAWARE CHANCERY COURT Fairfield, CT – March 25, 2019 – Calmare Therapeutics Incorporated, (OTC: CTTC), the pain mitigation company (“Calmare” or the “Company”), announced today that, on March 15, 2019, Calmare won two significant rulings from the Delaware Court of Chancery brought against it and certain of |
|
| March 25, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2019 (March 25, 2019) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File |
|
| March 18, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2019 (March 12, 2019) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File |
|
| February 14, 2019 |
CTTC / Calmare Therapeutics Inc. / BARD ASSOCIATES INC - CALMARE THERAPEUTICS 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Calmare Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| July 2, 2018 |
CALMARE THERAPEUTICS INCORPORATED REPORTS FINAL TALLY OF CONSENTS BY SHAREHOLDERS OF RECORD Exhibit 99.1 CALMARE THERAPEUTICS INCORPORATED REPORTS FINAL TALLY OF CONSENTS BY SHAREHOLDERS OF RECORD Fairfield, CT – July 2, 2018 – Calmare Therapeutics Incorporated, (OTC: CTTC) (“CTI”), the pain mitigation company (“Calmare”), today reported the final tabulation of consents by shareholders of record as tallied and prepared by IVS Associates Inc., a professional services organization speciali |
|
| July 2, 2018 |
Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2018 (June 8, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File Nu |
|
| July 2, 2018 |
CTTC / Calmare Therapeutics Inc. 8-K/A DEFA14A 1 s1112038ka.htm 8-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2018 (June 8, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other j |
|
| July 2, 2018 |
Exhibit 99.1 CALMARE THERAPEUTICS INCORPORATED REPORTS FINAL TALLY OF CONSENTS BY SHAREHOLDERS OF RECORD Fairfield, CT – July 2, 2018 – Calmare Therapeutics Incorporated, (OTC: CTTC) (“CTI”), the pain mitigation company (“Calmare”), today reported the final tabulation of consents by shareholders of record as tallied and prepared by IVS Associates Inc., a professional services organization speciali |
|
| June 14, 2018 |
Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2018 (June 8, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File Num |
|
| June 14, 2018 |
CALMARE THERAPEUTICS REPORTS PRELIMINARY TALLY OF CONSENTS BY SHAREHOLDERS Exhibit 99.1 CALMARE THERAPEUTICS REPORTS PRELIMINARY TALLY OF CONSENTS BY SHAREHOLDERS Fairfield, CT – June 14, 2018 – Calmare Therapeutics Incorporated (OTC: CTTC) (“CTI”), a pain mitigation company (“Calmare”), today reported the preliminary tally of consents by shareholders with respect to a recent consent solicitation neither supported by Calmare's officers nor by four of its five directors. |
|
| June 14, 2018 |
Exhibit 99.1 CALMARE THERAPEUTICS REPORTS PRELIMINARY TALLY OF CONSENTS BY SHAREHOLDERS Fairfield, CT – June 14, 2018 – Calmare Therapeutics Incorporated (OTC: CTTC) (“CTI”), a pain mitigation company (“Calmare”), today reported the preliminary tally of consents by shareholders with respect to a recent consent solicitation neither supported by Calmare's officers nor by four of its five directors. |
|
| June 14, 2018 |
CTTC / Calmare Therapeutics Inc. 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2018 (June 8, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File Num |
|
| May 3, 2018 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2018 (April 27, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File Num |
|
| May 3, 2018 |
CTTC / Calmare Therapeutics Inc. 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2018 (April 27, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission File Num |
|
| March 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE March 23, 2018 Conrad Mir Chief Executive Officer Calmare Therapeutics Inc. 1375 Kings Highway - Suite 400 Fairfield, CT 06824 Re: Calmare Therapeutics, Inc. DEFR14A definitive proxy statement filing made on Schedule 14A Filed on January 16, 2018 by Calmare Therapeutics, Inc. File No. 001-08696 |
|
| February 20, 2018 |
CTTC / Calmare Therapeutics Inc. DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A CONSENT STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant x Check the appropriate Box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by rule 14a-6(e)(2)) ? Definitive Proxy |
|
| February 20, 2018 |
8-K 1 s1091138k.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2018 (February 15, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other |
|
| February 20, 2018 |
CTTC / Calmare Therapeutics Inc. 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2018 (February 15, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission |
|
| February 16, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2018 (February 12, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission |
|
| February 16, 2018 |
CTTC / Calmare Therapeutics Inc. DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A CONSENT STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant x Check the appropriate Box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by rule 14a-6(e)(2)) ? Definitive Proxy |
|
| February 15, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2018 (February 15, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission |
|
| February 15, 2018 |
CTTC / Calmare Therapeutics Inc. 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2018 (February 15, 2018) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission |
|
| February 14, 2018 |
CTTC / Calmare Therapeutics Inc. / Finley Joseph Michael - SCHEDULE 13G AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 - Exit Filing)* Calmare Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2018 |
CTTC / Calmare Therapeutics Inc. / BARD ASSOCIATES INC - CALMARE THERAPEUTICS Passive Investment SC 13G 1 r13g123117cttc.txt CALMARE THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Calmare Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 9, 2018 |
CTTC / Calmare Therapeutics Inc. DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A CONSENT STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant x Check the appropriate Box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by rule 14a-6(e)(2)) ? Definitive Proxy |
|
| January 16, 2018 |
CTTC / Calmare Therapeutics Inc. DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A INFORMATION Consent Revocation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| January 12, 2018 |
CTTC / Calmare Therapeutics Inc. PRER14A PRER14A 1 s108710prer14a.htm PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A INFORMATION Consent Revocation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Consent Revocation Statement: Amendment No. 1 ☐ Confidential, for |
|
| January 11, 2018 |
CTTC / Calmare Therapeutics Inc. CORRESP January 11, 2018 VIA EDGAR AND EMAIL Nicholas P. Panos, Esquire Senior Special Counsel Office of Mergers & Acquisitions U.S. Securities and Exchange Commission 100 F Street NE Washington, D.C. 20549 Re: Calmare Therapeutics, Inc. PRE 14A preliminary proxy statement filing made on Schedule 14A Filed on January 2, 2018 File No. 001-08696 Dear Mr. Panos, We are writing on behalf of our client, Calmar |
|
| January 10, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE January 8, 2018 Conrad Mir Chief Executive Officer Calmare Therapeutics Inc. 1375 Kings Highway - Suite 400 Fairfield, CT 06824 Re: Calmare Therapeutics, Inc. PRE 14A preliminary proxy statement filing made on Schedule 14A Filed on January 2, 2018 by the Calmare Therapeutics, Inc. File No. 001-0 |
|
| January 6, 2018 |
CALMARE THERAPEUTICS CAUTIONS SHAREHOLDERS EXHIBIT 99.1 COMPANY NEWS FOR IMMEDIATE RELEASE CALMARE THERAPEUTICS CAUTIONS SHAREHOLDERS Fairfield, CT – December 20, 2017 – Calmare Therapeutics Incorporated, (OTCQB: CTTC) (“CTI”), the pain mitigation company (“Calmare”), today confirmed that a definitive consent solicitation statement has been filed with the U.S. Securities and Exchange Commission (“SEC”) by a minority complaining group of st |
|
| January 6, 2018 |
Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2018 (December 19, 2017) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission F |
|
| January 6, 2018 |
CTTC / Calmare Therapeutics Inc. 8-K DEFA14A 1 s1086518k.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2018 (December 19, 2017) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or othe |
|
| January 6, 2018 |
Press release entitled "Calmare Therapeutics Cautions Shareholder" dated December 19, 2017 EXHIBIT 99.1 COMPANY NEWS FOR IMMEDIATE RELEASE CALMARE THERAPEUTICS CAUTIONS SHAREHOLDERS Fairfield, CT ? December 20, 2017 ? Calmare Therapeutics Incorporated, (OTCQB: CTTC) (?CTI?), the pain mitigation company (?Calmare?), today confirmed that a definitive consent solicitation statement has been filed with the U.S. Securities and Exchange Commission (?SEC?) by a minority complaining group of st |
|
| December 29, 2017 |
CTTC / Calmare Therapeutics Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A INFORMATION Consent Revocation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Consent Revocation Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under Rule 14a-12 CALMARE THERAPEUTICS INCORPORATED (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Copies to: Alan Talesnick, Esq. |
|
| December 21, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2017 (December 11, 2017) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commissi |
|
| December 21, 2017 |
Letter of BDO USA, LLP dated December 19, 2017 Exhibit 16.1 Tel: 203-905-6300 Fax: 203-905-6301 www.bdo.com 1055 Washington Blvd, 5th Floor Stamford, CT 06901 December 19, 2017 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We read Item 4.01 of Form 8-K of Calmare Therapeutics Incorporated dated December 15, 2017. We agree with the statements made in response to that Item insofar as they relate to our Firm except a |
|
| December 18, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 18, 2017 (December 12, 2017) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission |
|
| December 16, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2017 (December 11, 2017) CALMARE THERAPEUTICS INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction (Commission |
|
| December 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE December 1, 2017 Stanley Yarbro Yarbro Consulting 154 Quail Hollow Dr. Kings Mountain, NC 28086 Re: Calmare Therapeutics, Inc. PREN14A preliminary proxy statement filing made on Schedule 14A Filed on November 22, 2017 by the Calmare Committee to Restore Stockholder Value File No. 001-08696 Dear |
|
| November 15, 2017 |
CTTC / Calmare Therapeutics Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ?Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2017 |
|
| September 21, 2017 |
Form of Stockholder Proposal, including Nominee Agreement EXHIBIT 4 Form of Stockholder Proposal, including Nominee Agreement August 10, 2017 Calmare Therapeutics Incorporated c/o Corporate Secretary 1375 Kings Highway East, Suite 400 Fairfield, Connecticut 06824 Re: Notice of Stockholder Proposal to Nominate Directors for Election at the Annual Meeting Dear Sir/Madam: This Notice of the Stockholders’ proposal to nominate directors for election at the annual meeting of Calmare Therapeutics Incorporated (the “Company”) (the “Notice of Stockholder Proposal”) is hereby delivered to the Secretary of the Company in accordance with Section 1. |
|
| September 21, 2017 |
CTTC / Calmare Therapeutics Inc. / Yarbro Stan - SC 13D/A Activist Investment SC 13D/A 1 v475565sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Calmare Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) Jason Moreau and Sarah McGarrell Pierce Atwood, LLP 100 Summer Street Boston, MA 02110 (Name, |
|
| September 21, 2017 |
Form of Letter to the Board of Directors EX-3 2 v475565ex99-3.htm EXHIBIT 3 EXHIBIT 3 Form of Letter to the Board of Directors To: Board of Directors and Management of Calmare Therapeutics, Inc. From: Stan Yarbro on behalf of the ‘Group’ as set forth in the Scheduled 13D filed on June 30, 2017 Date: July 14, 2017 Subject: Request for Meeting with Calmare Board of Directors and Management Gentlemen, It has now been over two weeks since th |
|
| September 14, 2017 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2017 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) |
|
| September 14, 2017 |
Letter from Mayer Hoffman McCann CPAs, dated September 14, 2017 Exhibit 16.1 September 14, 2017 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Mesdames: We have read Item 4.01 of Calmare Therapeutics Incorporated Form 8-K dated September 14, 2017, and have the following comments: 1. We agree with the statements made in the first, second, third and fourth paragraphs of Item 4.01(a). 2. We have no basis on which to ag |
|
| August 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ?Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2017 ? Tra |
|
| July 21, 2017 |
CTTC / Calmare Therapeutics Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 |
|
| June 30, 2017 |
CTTC / Calmare Therapeutics Inc. / Yarbro Stan - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Calmare Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) Jason Moreau and Sarah McGarrell Pierce Atwood, LLP 100 Summer Street Boston, MA 02110 (Name, Address and Telephone Number of Person Aut |
|
| June 30, 2017 |
Joint Filing Agreement, dated June 30, 2017 PURSUANT TO RULE 13d-1(k) EXHIBIT 2 Joint Filing Agreement, dated June 30, 2017 PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| June 30, 2017 |
EXHIBIT 1 June 30, 2017 Board of Directors Calmare Therapeutics, Inc. 1375 Kings Highway, Suite 400 Fairfield, CT 06824-5380 [email protected] Dear Members of the Board: As shareholders of Calmare Therapeutics, Inc. (“Calmare” or the “Company”) who collectively own more than 22% (22.3%) of the common stock of Calmare, we write to express our ongoing concern and extreme disappointment reg |
|
| March 31, 2017 |
Calmare Therapeutics NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): xForm 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2016 ? |
|
| March 23, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2017 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) (C |
|
| February 23, 2017 |
CALMARE THERAPEUTICS BOARD OF DIRECTORS CHANGES Exhibit 99.1 COMPANY NEWS CALMARE THERAPEUTICS BOARD OF DIRECTORS CHANGES Fairfield, CT ? February 23, 2017 ? Calmare Therapeutics Incorporated, (OTCQB: CTTC) (the ?Company? or ?CTI), ?the pain mitigation company,? has announced the following changes to its Board of Directors: A. Messrs. Robert Conway, Jr., and Steven Roehrich have stepped down in order to pursue other endeavors, contemporaneous w |
|
| February 23, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2017 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) |
|
| February 14, 2017 |
CTTC / Calmare Therapeutics Inc. / BARD ASSOCIATES INC - CALMARE THERAPEUTICS Passive Investment SC 13G 1 r13g123116cttc.txt CALMARE THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Calmare Therapeutics (Name of Issuer) Common Stock, Warrants (Title of Class of Securities) 204512107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| December 29, 2016 |
Calmare Therapeutics 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-08696 CALMAR |
|
| November 21, 2016 |
8-K 1 s1047458k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2016 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdi |
|
| November 21, 2016 |
Exhibit 99.1 |
|
| November 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ?Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2016 |
|
| October 25, 2016 |
DEF 14A 1 s104424def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| August 22, 2016 |
Calmare Therapeutics FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-08696 CALMARE THE |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Tr |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Tr |
|
| May 19, 2016 |
Calmare Therapeutics FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-08696 CALMARE TH |
|
| May 17, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response?????????... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ?Form 10-K o Form 20-F o Form 11-K ? Form 10-Qo Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 20 |
|
| April 14, 2016 |
Calmare Therapeutics FORM 10-K (Annual Report) 10-K 1 s10302010k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH |
|
| April 14, 2016 |
Exhibit 10.44 EMPLOYMENT SERVICES AGREEMENT This Employment Services Agreement (the ?Agreement?) is entered into as of the 15th day of January 2016 by and between Calmare Therapeutics, Inc., a Delaware corporation, with a business address of 1375 Kings Highway East, Fairfield, CT 06824 (the ?Company?), and Dr. Christine Chansky (?Executive?). INTRODUCTION WHEREAS, the Company desires to employ the |
|
| April 14, 2016 |
Exhibit 10.45 EMPLOYMENT SERVICES AGREEMENT This Employment Services Agreement (the ?Agreement?) is entered into as of the 11th day of April, 2016 by and between Calmare Therapeutics, Inc., a Delaware corporation, with a business address of 1375 Kings Highway East, Fairfield, CT 06824 (the ?Company?), and Thomas P. Richtarich (?Executive?). INTRODUCTION WHEREAS, the Company desires to employ the E |
|
| March 31, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response?????????... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ?Form 10-K o Form 20-F o Form 11-K ?Form 10-Qo Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2 |
|
| March 1, 2016 |
Exhibit 99.1 Calmare Therapeutics Incorporated Appoints Christine Chansky, M.D., J.D., F.C.L.M., Chief Regulatory Officer? February 17, 2016 02:45 PM Eastern Standard Time FAIRFIELD, Conn.?(BUSINESS WIRE) ? Calmare Therapeutics Incorporated, (OTCQB:CTTC) (CTI), the Calmare? chronic pain and wound care company, has appointed Dr. Christine Chansky, M.D., J.D., F.C.L.M., chief regulatory officer (CRO |
|
| March 1, 2016 |
Exhibit 10.3 Conrad Mir President & CEO [email protected] January 15, 2016 Christine Chansky, MD, JD Westfield, NJ [email protected] Re: Employment Term Sheet Dear Dr. Chansky; As per our conversations, I am pleased to confirm Calmare Therapeutics Incorporated?s (CTI) offer of employment as follows. Upon your approval, we will draft a formal employment agreement which will includ |
|
| March 1, 2016 |
Calmare Therapeutics FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-08696 CALMAR |
|
| February 1, 2016 |
CTTC / Calmare Therapeutics Inc. / BARD ASSOCIATES INC - CALMARE THERAPEUTICS Passive Investment SC 13G 1 r13g123115cttc.txt CALMARE THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Calmare Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 15, 2016 |
8-K 1 s1024998k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2016 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdic |
|
| January 15, 2016 |
8-K 1 s1024998k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2016 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdic |
|
| October 23, 2015 |
8-K 1 s1020238k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2015 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdi |
|
| October 23, 2015 |
Amended and Restated Bylaws of Calmare Therapeutics Incorporated ARTICLE I MEETING OF STOCKHOLDERS Exhibit 3.1 Amended and Restated Bylaws of Calmare Therapeutics Incorporated ARTICLE I MEETING OF STOCKHOLDERS SECTION 1.01. Annual Meetings. The annual meeting of stockholders for the election of Directors and for the transaction of such other proper business, notice of which is given in the notice of the meeting, shall be held on such date and at such time and place, within or without the State |
|
| October 23, 2015 |
Company Presentation October 2015 © 2015 Calmare Therapeutics Incorporated Exhibit 99.1 Company Presentation October 2015 ? 2015 Calmare Therapeutics Incorporated THIS PRESENTATION CONTAINS ?FORWARD-LOOKING STATEMENTS? WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY, OR |
|
| September 25, 2015 |
Exhibit 99.1 CORPORATE NEWS FOR IMMEDIATE RELEASE CALMARE THERAPEUTICS INCORPORATED APPOINTS STEPHEN J. D?AMATO, M.D., F.A.C.E.P. CHIEF MEDICAL OFFICER Fairfield, CT ? September 15, 2015 ? Calmare Therapeutics Incorporated (OTCQB: CTTC) (CTI), the Calmare? pain mitigation company, has appointed Stephen J. D?Amato, M.D., F.A.C.E.P., chief medical officer (CMO) of Calmare Therapeutics. As part of Dr |
|
| September 25, 2015 |
Calmare Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2015 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation |
|
| September 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 26, 2015 |
Exhibit 99.2 EARNINGS NEWS FOR IMMEDIATE RELEASE CALMARE THERAPEUTICS REPORTS YEAR END; FOURTH QUARTER 2014 RESULTS Year-on-year: revenues up 60%; Device sales up 88%; G&A Down 22% FOURTH QUARTER: REVENUES DOWN 52%; device sales down 33%; G&A Down 14% Conference Call CTI will host an earnings conference call on Wednesday, July 1, 2015 at 10:00 A.M. EDT. To participate in the conference call, pleas |
|
| June 26, 2015 |
Calmare Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2015 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) (Co |
|
| June 26, 2015 |
Exhibit 99.1 DEFENSE NEWS FOR IMMEDIATE RELEASE CALMARE THERAPEUTICS AWARDED GSA CONTRACT EXTENSION Simple Buying Process of Calmare? Pain Therapy Devices and its Consumables for U.S. Military Hospitals, Clinics and Medical Practitioners Extended Fairfield, CT ? June 25, 2015 ? Calmare Therapeutics Incorporated, (OTCQB: CTTC) (CTI), the pain mitigation company, has been awarded a preliminary three |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response?????????... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ?Form 10-K o Form 20-F o Form 11-K ?Form 10-Qo Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2 |
|
| March 16, 2015 |
CTTC / Calmare Therapeutics Inc. / BARD ASSOCIATES INC - CALMARE WITH WARRANTS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Calmare Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 17, 2015 |
CTTC / Calmare Therapeutics Inc. / BARD ASSOCIATES INC - CALMARE THERAPEUTICS Passive Investment SC 13G 1 r13g123114cttc.txt CALMARE THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Calmare Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 204512107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 6, 2015 |
CTTC / Calmare Therapeutics Inc. / Finley Joseph Michael - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Calmare Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 204 512 107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| December 9, 2014 |
CTTC / Calmare Therapeutics Inc. 8-A12G - - 8-A12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A12(G) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CALMARE THERAPEUTICS INCORPORATED (Exact name of Registrant as specified in its charter) Delaware 36-2664428 (State or other jurisdiction (IRS Employer of Incorporation) Identification Number) |
|
| November 14, 2014 |
CTTC / Calmare Therapeutics Inc. NT 10-Q - - FORM NT 10-Q NT 10-Q 1 v394495nt10-q.htm FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ¨Form 10-K o Form 20-F o Form 11-K ý Form 10-Qo Form 10-D o Form N-SAR o F |
|
| November 14, 2014 |
CTTC / Calmare Therapeutics Inc. RW - - FORM RW Calmare Therapeutics Incorporated 1375 Kings Highway East Fairfield, CT 06824 33321 November 13, 2014 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street N. |
|
| November 12, 2014 |
8-K 1 v3902588k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2014 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jur |
|
| September 2, 2014 |
8-K 1 v3882108k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2014 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other juris |
|
| August 20, 2014 |
Exhibit 3.1 |
|
| August 20, 2014 |
Exhibit 99.1 Annual General Meeting August 2014 © 2014 Calmare Therapeutics, Inc.. THIS PRESENTATION CONTAINS “FORWARD - LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD - LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY, OR I |
|
| August 20, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2014 Calmare Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) ( |
|
| July 31, 2014 |
CTTC / Calmare Therapeutics Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| July 16, 2014 |
CTTC / Calmare Therapeutics Inc. PRE 14A - - PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: þ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| May 29, 2014 |
Competitive Technologies Names Ian Rhodes, CPA As New Chief Financial Officer Competitive Technologies Names Ian Rhodes, CPA As New Chief Financial Officer PR Newswire FAIRFIELD, Conn. |
|
| May 29, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2014 Competitive Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) (Commis |
|
| May 28, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2014 Competitive Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) (Commis |
|
| May 28, 2014 |
EX-99.1 2 v379942ex99-1.htm EXHIBIT 99.1 Investor Presentation FIRST QUARTER 2014 Unlocking the Potential of Innovation © 2014 Competitive Technologies, Inc THIS PRESENTATION CONTAINS “FORWARD - LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD - LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY |
|
| April 29, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2014 Competitive Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) (Comm |
|
| April 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): ý Form 10-K o Form 20-F o Form 11-K ¨ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31 |
|
| March 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2014 Competitive Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) (C |
|
| February 4, 2014 |
CTTC / Calmare Therapeutics Inc. / Finley Joseph Michael - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Competitive Technologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 204 512 107 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 23, 2014 |
CTTC / Calmare Therapeutics Inc. / Tonaquint, Inc. - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Competitive Technologies, Inc. (Name of Issuer) Common Stock $0.01 par value (Title of Class of Securities) 204512107 (CUSIP Number) January 23, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| December 10, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2013 Competitive Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) (Co |
|
| December 10, 2013 |
EX-99.1 2 f8k120513ex99icompetitive.htm COMPANY INFORMATION INVESTOR PRESENTATION FOURTH QUARTER 2013 DATED DECEMBER 5, 2013 (FURNISHED HEREWITH). Exhibit 99.1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
|
| November 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-08696 CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q oForm 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2013 o |
|
| October 4, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2013 Competitive Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-08696 36-2664428 (State or other jurisdiction of incorporation) ( |
|
| October 4, 2013 |
EX-99.1 3 v356721ex99-1.htm EXHIBIT 99.1 CORPORATE NEWS FOR IMMEDIATE RELEASE COMPETITIVE TECH APPOINTS CONRAD F. MIR AS NEW PRESIDENT, CEO & MEMBER OF THE BOARD Seasoned Turnaround CEO and Microcap Healthcare Executive Helped Raise More Than $40 Million For Distressed Biotech Companies Fairfield, CT – October 4, 2013 – The Board of Directors of Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), |
|
| September 27, 2013 |
CTTC / Calmare Therapeutics Inc. / Asc Recap Llc - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 COMPETITIVE TECHNOLOGIES, INC. Common Stock, par value $0.01 CUSIP # 204512107 September 16, 2013 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13d-1(d) The remainder of this cover page shal |
|
| September 17, 2013 |
Unregistered Sales of Equity Securities - COMPETITIVE TECHNOLOGIES, INC. CURRENT REPORT ON FORM 8-K SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| September 13, 2013 |
Converted by EDGARwiz As filed with the Securities and Exchange Commission on June 28, 2013, and amended on September 12, 2013. |
|
| September 13, 2013 |
begin 644 cttcs1a1.pdf M)5!$1BTQ+C4-)>+CS],-"C0R-R`P(&]B:@T\/"],:6YE87)I>F5D(#$O3"`U M-#0V,#%LT,C<@ M,35=+TEN9F\@-#(V(#`@4B],96YG=&@@-#@O4')E=B`U-#,W,C@O4F]O="`T M,C@@,"!2+U-I>F4@-#0R+U1Y<&4O6%)E9B]76S$@,B`Q73X^H-"F5N9'-TN,TH7IY)\>6 M&DNV3R7*"B>E>46T5KC-F'K1*[']\3$N&Y%GB@<8F)X[S-JP**GT2"JKB.JD MT)@)#()J5!8L9DAON.LDP'*= MU<;AP[P;IP0['ITXWC2138G'H63FP=H';Y^DNU>(ZJD?\%-8'"@5Q.LB?7SA M%%.J(;'$U\L=I.I$ |
|
| September 11, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| September 11, 2013 |
EQUITY PURCHASE AGREEMENT BY AND BETWEEN COMPETITIVE TEHNOLOGIES, INC. AND SOUTHRIDGE PARTNERS II, LP Dated September 10, 2013 THIS EQUITY PURCHASE AGREEMENT entered into as of the 10th day of September, 2013 (this "AGREEMENT"), by and between SOUTHRIDGE PARTNERS II, LP, a Delaware limited partnership ("INVESTOR"), and COMPETITIVE TECHNOLOGIES, INC., a Delaware corporation (the "COMPANY"). WHEREAS |
|
| September 9, 2013 |
- COMPETITIVE TECHNOLOGIES, INC. REGISTRATION STATEMENT ON FORM S-8 SEPTEMBER 9, 2013. UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COMPETITIVE TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE 36-2664428 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 1375 Kings Highway East, Suite 400 06824 (Addr |
|
| September 5, 2013 |
COMPETITIVE TECHNOLOGIES, INC. CONVERTIBLE PROMISSORY NOTE Converted by EDGARwiz Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT, dated as of July 16, 2013 (this “Agreement”), is entered into by and between COMPETITIVE TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and TONAQUINT, INC., a Utah corporation, its successors and/or assigns (“Buyer”). RECITALS: A. The Company and the Buyer are executing and delivering |
|
| September 5, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 12, 2013 |
CTTC / Calmare Therapeutics Inc. / Tonaquint, Inc. - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Competitive Technologies, Inc. (Name of Issuer) Common Stock ($0.01 par value) (Title of Class of Securities) 204512107 (CUSIP Number) August 09, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| July 26, 2013 |
Converted by EDGARwiz SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT, dated as of July 16, 2013 (this “Agreement”), is entered into by and between COMPETITIVE TECHNOLOGIES, INC. |
|
| July 26, 2013 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 22, 2013 |
Registration Statement - REGISTRATION STATEMENT ON FORM S-1 JUNE 28, 2013 Converted by EDGARwiz As filed with the Securities and Exchange Commission on June 28, 2013. |
|
| June 28, 2013 |
- REGISTRATION STATEMENT ON FORM S-8 JUNE 28, 2013 Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 27, 2013 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 31, 2013 |
- COMPETITIVE TECHNOLOGIES, INC. AMENDMENT 1 TO PROXY STATEMENT ORIGINALLY FILED MAY 10, 2013 Dear Fellow Shareholder: You are cordially invited to attend the Competitive Technologies, Inc. |
|
| May 10, 2013 |
- COMPETITIVE TECHNOLOGIES, INC. PROXY NOTICE MAY 10, 2013 Converted by EDGARwiz *** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on June 20, 2013 COMPETITIVE TECHNOLOGIES, INC. |
|
| May 10, 2013 |
- COMPETITIVE TECHNOLOGIES, INC. PROXY STATEMENT ON SCHEDULE 14(A) begin 644 cttcproxystatementmay102013.pdf M)5!$1BTQ+C4-)>+CS],-"C$T."`P(&]B:@T\/"],:6YE87)I>F5D(#$O3"`Q M.#8Q.#%LQ-#@@ M,S5=+TEN9F\@,30W(#`@4B],96YG=&@@.3,O4')E=B`Q.#4V-#8O4F]O="`Q M-#D@,"!2+U-I>F4@,3@S+U1Y<&4O6%)E9B]76S$@,R`Q73X^^!2#Y&(/G0A@#$]`N9;!Z!D::D/\9&.,^`@08``]R M#3X-"F5N9'-T8F!@8&9@8/)D8`&2 MQ@R"#`@@")1A!8IS'$`29&B8-K^!@;%AP7R#;@F9#-4NT7>,8=R[+3B:4A=T+5#8/#&<7@6%+9JD*>*IVL#` M)&EGP#//XH! |
|
| May 10, 2013 |
- COMPETITIVE TECHNOLOGIES, INC. PROXY CARD begin 644 cttcproxycard.pdf M)5!$1BTQ+C0-)>+CS],-"C0Q(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#,@,5T^/G-TQ!)%,:B.3N!K/7@,FM())1#TQV@$5N@!)$^E\$BWT`D;S2(]%L.)!G]A4!L?B\0R;H:K,8%;$(VF)0&D7PGP.P0 M,&D)5B,'9@N"25FP"">8K0HB.7K!['@0*=0.EJT#BRP%^V@I=C86$4D0R3,3 M[(;-8'/*P>17$.EX">1^SQ<@[email protected]`I+;IUB8`*&X0ZP:0R,HR3)Y'\& MIIXS``$&`.4H(I0-"F5N9'-T$#`^-JCL8.,!L)&$,Q`\-2 MH!8#AW4)+#*,`@Q*#GP&+%<8Q1D,&+@2%";XZ#&$ |
|
| May 10, 2013 |
- COMPETITIVE TECHNOLOGIES, INC. PROXY STATEMENT ON SCHEDULE 14(A) Converted by EDGARwiz Dear Fellow Shareholder: You are cordially invited to attend the Competitive Technologies, Inc. |
|
| May 10, 2013 |
- COMPETITIVE TECHNOLOGIES, INC. PROXY NOTICE MAY 10, 2013 begin 644 cttcproxynotice.pdf M)5!$1BTQ+C0-)>+CS],-"C0T(#`@;V)J#3P\+TQI;F5AF4@,3`Y+U1Y<&4O6%)E9B]76S$@,R`Q73X^`2/4L$,F=#B*U'X!(Z1@0J10%(J5$ MP;HV(TB&S>@BN,2A(A(@4O(4D&3T%P*Q`W^"2'XO$"F8`"(%C$"D6#6(Y&0$ MD5Q-0/*,E`7T!>[P:8Q,`XQ\C\#$\8F!@8&9@8"IC8&5@8"UA$&9``&&@&"L#"P/'32^&&;L5UD4$1C0P,,Q2 M"D!2PR#?TVIX0;ZG,^C&=3O!*2\?],S[P=$!!0T:0`SC670T(`P!`A$&UC5I M0%H.B!7`(IL9A!A$&JH:V%O4MC/E,BVZD+5$<3D;5#DF2&5C |
|
| May 10, 2013 |
- COMPETITIVE TECHNOLOGIES, INC. PROXY CARD Converted by EDGARwiz COMPETITIVE TECHNOLOGIES, INC. 1375 KINGS HIGHWAY EAST SUITE 400 FAIRFIELD, CT 06824 VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the inst |
|
| April 1, 2013 |
- NOTICE OF INABILITY TO TIMELY FILE FORM 10-K U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-8696 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2012 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ |
|
| March 5, 2013 |
- REGISTRATION STATEMENT ON FORM S-8 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COMPETITIVE TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE 36-2664428 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 1375 Kings Highway East, Suite 400 06824 (Addr |
|
| February 26, 2013 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 26, 2013 |
EQUITY PURCHASE AGREEMENT BY AND BETWEEN COMPETITIVE TEHNOLOGIES, INC. AND SOUTHRIDGE PARTNERS II, LP Dated February , 2013 THIS EQUITY PURCHASE AGREEMENT entered into as of the day of February, 2013 (this "AGREEMENT"), by and between SOUTHRIDGE PARTNERS II, LP, a Delaware limited partnership ("INVESTOR"), and COMPETITIVE TECHNOLOGIES, INC., a Delaware corporation (the "COMPANY"). WHEREAS, the par |
|
| February 26, 2013 |
COMPETITIVE TECHNOLOGIES, INC. PROMISSORY NOTE DUE DECEMBER 31, 2013 NEITHER THIS SECURITY NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE OR UNDER THE SECURITIES ACT OF 1933, AS AMENDED NEITHER THIS SECURITY NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE OR UNDER THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| February 26, 2013 |
REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement ("Agreement"), dated February , 2013, is made by and between COMPETITIVE TECHNOLOGIES, INC. |
|
| February 12, 2013 |
CTTC / Calmare Therapeutics Inc. / Finley Joseph Michael - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Competitive Technologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 204 512 107 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 5, 2013 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 15, 2012 |
- COMPETITIVE TECHNOLOGIES NOTICE OF INABILITY TO TIMELY FILE FORM 10-Q U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-8696 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2012 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ |
|
| October 31, 2012 |
PAIN THERAPY MEDICAL DEVICE Exhibit 10.1 October 25, 2012 Carl D. O’Connell 116 Main Street Irvington, NY 10533 Dear Carl, Further to your recent conversation with Bob Moussa, I am pleased to confirm our offer of employment as follows: 1) Position Title: President/CEO Competitive Technologies, Inc. 2) Trial Period: Mutually agreed to be 60 (sixty) days from starting date. 3) Base salary: $ 250,000 |
|
| October 31, 2012 |
COMPETITIVE TECHNOLOGIES, INC. APPOINTS CARL O’CONNELL CHIEF EXECUTIVE OFFICER PAIN THERAPY MEDICAL DEVICE Exhibit 99.1 For immediate release COMPETITIVE TECHNOLOGIES, INC. APPOINTS CARL O’CONNELL CHIEF EXECUTIVE OFFICER Fairfield, CT – (October 29, 2012) – Competitive Technologies, Inc. (OTCQX: CTTC) announced today that its Board of Directors has named Carl O’Connell as President and Chief Executive Officer. Mr. O’Connell replaces Johnnie D. Johnson, interim Chief Executiv |
|
| October 31, 2012 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 14, 2012 |
U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-8696 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2012 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tr |
|
| July 6, 2012 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 6, 2012 |
AMENDMENT Exhibit 10.1 Amendment to the Amended, Restated and Extended Service and Representation Agreement effective April 1, 2011 between Professor Giuseppe Marineo, Delta Research and Development and Competitive Technologies, Inc. AMENDMENT No. 1 This AMENDMENT ("Agreement") effective as of June 30, 2012 (Effective Date") by mutual consent of Competitive Technologies, Inc., a Delaware corporati |
|
| July 6, 2012 |
PAIN THERAPY MEDICAL DEVICE Exhibit 99.1 Draft For immediate release COMPETITIVE TECHNOLOGIES EXTENDS AGREEMENT FOR CALMARE® SCRAMBLER THERAPY® PAIN TREATMENT DEVICE TO TEN YEARS Fairfield, CT – (July 6, 2012) – Competitive Technologies, Inc. (OTCQX: CTTC) announced today that is has negotiated a five-year extension to its agreement for the Calmare® pain therapy device utilizing "Scrambler Therapy |
|
| June 7, 2012 |
- COMPETITIVE TECHNOLOGIES, INC. REGISTRATION STATEMENT ON FORM S-8 FILED JUNE 6, 2012 Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 30, 2012 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 15, 2012 |
U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-8696 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2012 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] T |
|
| April 19, 2012 |
begin 644 cttcproxystatementa1.pdf M)5!$1BTQ+C4-)>+CS],-"C$T-"`P(&]B:@T\/"],:6YE87)I>F5D(#$O3"`Q M.#(U-#,O3R`Q-#8O12`W.#0T,"].(#(V+U0@,3@R,#`T+T@@6R`U,#0@,S,Y M73X^#65N9&]B:@T@("`@("`@("`@("`@#0HQ-C$@,"!O8FH-/#PO1&5C;V1E M4&%R;7,\/"]#;VQU;6YS(#4O4')E9&EC=&]R(#$R/CXO1FEL=&5R+T9L871E M1&5C;V1E+TE$6SQ$-D%$,T0R-3%LQ-#0@ M,S5=+TEN9F\@,30S(#`@4B],96YG=&@@.34O4')E=B`Q.#(P,#4O4F]O="`Q M-#4@,"!2+U-I>F4@,3< |
|
| April 19, 2012 |
Converted by EDGARwiz Dear Fellow Shareholder: You are cordially invited to attend the Competitive Technologies, Inc. |
|
| April 16, 2012 |
- COMPETITIVE TECHNOLOGIES, INC. PROXY NOTICE FOR THE ANNUAL SHAREHOLDER MEETING APRIL 2012 begin 644 cttcproxynoticeapril2012.pdf M)5!$1BTQ+C0-)>+CS],-"C0T(#`@;V)J#3P\+TQI;F5AF4@,3`P+U1Y<&4O6%)E9B]76S$@,R`Q73X^5#S!/)FI69]+0>H#Q!@Q!K9D9B#-",37`0(, M`#KO%-8-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-#8@ M,"!O8FH-/#PO0V]N=&5N=',@-#<@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]087)E;G0@-#(@,"!2+U)E)PKY'(*X3(V4S`W-5,(2>%R#>$*Y"I4,%0P`$((F9RK MH!^19JC@DJ\0R`4`ZSD)]@T*96YD[EW4LO=: |
|
| April 16, 2012 |
- COMPETITIVE TECHNOLOGIES, INC. PROXY NOTICE FOR THE ANNUAL SHAREHOLDER MEETING APRIL 2012 Converted by EDGARwiz COMPETITIVE TECHNOLOGIES, INC. 1375 KINGS HIGHWAY EAST SUITE 400 FAIRFIELD, CT 06824 VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the inst |
|
| April 13, 2012 |
- COMPETITIVE TECHNOLOGIES, INC. DEFINITIVE PROXY STATEMENT FOR THE 2012 ANNUAL SHAREHOLDER MEETING begin 644 cttcproxystatementapril2012.pdf M)5!$1BTQ+C4-)>+CS],-"C$T-"`P(&]B:@T\/"],:6YE87)I>F5D(#$O3"`Q M.#(T,3@O3R`Q-#8O12`W.#0T-"].(#(V+U0@,3@Q.#@P+T@@6R`U,#0@,S,Y M73X^#65N9&]B:@T@("`@("`@("`@("`@#0HQ-C$@,"!O8FH-/#PO1&5C;V1E M4&%R;7,\/"]#;VQU;6YS(#4O4')E9&EC=&]R(#$R/CXO1FEL=&5R+T9L871E M1&5C;V1E+TE$6SQ#,S!#,D9&1$(T0S,S0C@P-D4Q.#1!,#1$0T4W.#)%-3X\ M-C%%.3@X-40X-D,Q.#8T,SA!,CDX,#%LQ-#0@ M,S5=+TEN |
|
| April 13, 2012 |
- COMPETTIIVE TECHNOLOGIES, INC. PROXY CARD FOR THE ANNUAL SHAREHOLDER MEETING 2012 Converted by EDGARwiz *** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on May 24, 20 12 COMPETITIVE TECHNOLOGIES, INC. |
|
| April 13, 2012 |
begin 644 cttcproxycardapril2012.pdf M)5!$1BTQ+C0-)>+CS],-"C0Y(#`@;V)J#3P\+TQI;F5AF4@.#@O5'EP92]84F5F+U=;,2`S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8#H$(AGM023#/C"[#$2RYH%(F6@0J10%(J7$0:3!6Q#I+P0D&0- M@MB"S6#2"$1J/P"1;)(@DJL)2#)E`"2?QJW,C`!;3P(MH6!D4[D?P;&8^\` M`@P`CI003`T*96YDQL"!(&">S<`"8X4S842+@$=#1TP@%``!&(, MG(^R@;0`$`N!1%LP(#`@-C$R(#,Y-ETO365D:6%";WA;,"`P(#8Q,B`S.39= M+U!A'0O M26UA9V5"+TEM86=E0R] |
|
| April 13, 2012 |
- COMPETITIVE TECHNOLOGIES, INC. DEFINITIVE PROXY STATEMENT FOR THE 2012 ANNUAL SHAREHOLDER MEETING Converted by EDGARwiz Dear Fellow Shareholder: You are cordially invited to attend the Competitive Technologies, Inc. |
|
| April 3, 2012 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 30, 2012 |
U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-8696 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2011 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ |
|
| March 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2012 (March 1, 2012) Competitive Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 1-8696 36-2664428 (State or Other Jurisdiction of Incorpor |
|
| February 24, 2012 |
- COMPETITIVE TECHNOLOGIES, INC. REGISTRATION STATEMENT ON FORM S-8 FILED FEBRUARY 24, 2012 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COMPETITIVE TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE 36-2664428 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 1375 Kings Highway East, Suite 400 06824 (Addr |
|
| February 1, 2012 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 1, 2012 |
SETTLEMENT AGREEMENT AND GENERAL RELEASE Converted by EDGARwiz Exhibit 10.1 SETTLEMENT AGREEMENT AND GENERAL RELEASE This Settlement Agreement and General Release is made and entered into between JOHN B. NANO ("Nano") and COMPETITIVE TECHNOLOGIES, INC. ("CTT"). WHEREAS, in or around September 13, 2010, Nano filed a demand for arbitration with the American Arbitration Association (#12 166 00544 10) asserting claims of breach of contract a |
|
| January 30, 2012 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| January 17, 2012 |
January 17, 2012 Via E-mail Johnnie D. Johnson Chief Executive Officer and Chief Financial Officer Competitive Technologies, Inc. 777 Commerce Drive Fairfield, CT 06825 Re: Competitive Technologies, Inc. Form 10-K for the Fiscal Year Ended July 31, 2010 Filed October 27, 2010 File No. 001-08696 Dear Mr. Johnson: We have completed our review of your filings. We remind you that our comments or chang |
|
| January 13, 2012 |
Territory Exclusive License Agreement For Intellectual Property Exhibit 10.1 Territory Exclusive License Agreement For Intellectual Property AGREEMENT AGREEMENT EFFECTIVE as of September 25, 2007 "Effective Date") by mutual consent of Competitive Technologies, Inc., a Delaware corporation (hereinafter referred to as "CTT") a company having a place of business at: Competitive Technologies, Inc. 777 Commerce Dr. Fairfield, CT 06825 and Daeyang E&C Co., Ltd., a S |
|
| January 13, 2012 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| January 13, 2012 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| January 13, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*./@94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@," |
|
| January 13, 2012 |
MEMORANDUM OF UNDERSTANDING Exhibit 10.3 MEMORANDUM OF UNDERSTANDING The following describes the understanding of both GEOMC Co. Ltd ("GEOMC") and Competitive Technologies, Inc. ("CTT") regarding the revenue splits for sales of Calmare Therapy MC-5A Unit. 1. GEOMC will receive $[Confidential Information Omitted] for the sale of each unit. 2. Samples will be shipped at a cost of $[Confidential Info |
|
| January 13, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.,@94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@," |
|
| January 13, 2012 |
Amended, Restated and Extended Service and Representation Agreement Between TECHNOLOGY SERVICING AGREEMENT Exhibit 10.1 Amended, Restated and Extended Service and Representation Agreement Between Professor Giuseppe Marineo, Delta Research & Development and Competitive Technologies, Inc. AGREEMENT This AMENDED, RESTATED AND EXTENDED SERVICE AND REPRESENTATION AGREEMENT (“Agreement” or “SARA”) effective as of the 1st of April 2011 (“Effective Date”) by mutual consent of Com |
|
| January 13, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.<@94P`C$+`P<#`%4I6@[5T0;6Q:"R"7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+ |
|
| January 13, 2012 |
begin 644 cttc8kmarineoa1.pdf M)5!$1BTQ+C0-)>+CS],-"CD@,"!O8FH@/#PO3&EN96%R:7IE9"`Q+TP@-#8P M,CF4@ M,S$O4')E=B`T-3(,``.Q,2`@T*96YD%LP(#`@-C$R(#%LP(#`@-C$R(#7!E+U!A9V4^/@UE;F1O8FH-,3(@,"!O8FH\/"]83V)J96-T/#PO26TQ M(#(S(#`@4CX^+T-O;&]R4W!A8V4\/"]#7!E M+T9O;G0^/@UE;F1O8FH-,30@,"!O8FI;+TE#0T)A%LM-34X("TS,#<@,C`P M,"`Q,#(V72]!7!E+T9O;G1$97-C7!E+T5X=$=3=&%T92]302!F86QS92]332`P M+C`R/CX-96YD;V)J#3$W(#`@; |
|
| January 6, 2012 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 Post Effective Amendment No. 4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COMPETITIVE TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE 36-2664428 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 1375 Kings High |
|
| January 6, 2012 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida January 6, 2012 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief – Legal Melissa Walsh, Staff Accountant Securities and Exchange Commissio |
|
| December 27, 2011 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida December 26, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief – Legal Melissa Walsh, Staff Accountant Securities and Exchange Commiss |
|
| December 15, 2011 |
December 15, 2011 Via E-mail Johnnie D. Johnson Chief Executive Officer and Chief Financial Officer Competitive Technologies, Inc. 777 Commerce Drive Fairfield, CT 06825 Re: Competitive Technologies, Inc. Form 10-K/A for the Fiscal Year Ended July 31, 2010 Filed September 15, 2011 File No. 001-08696 Post-Effective Amendment No. 3 to Form S-8 Filed December 9, 2011 File No. 333-176389 Dear Mr. John |
|
| December 12, 2011 |
CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida December 12, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief – Legal Melissa Walsh, Staff Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4561 Re: Competitive Te |
|
| December 7, 2011 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida December 8, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief – Legal Melissa Walsh, Staff Accountant Securities and Exchange Commissi |
|
| November 17, 2011 | ||
| November 1, 2011 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida November 1, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief – Legal Melissa Walsh, Staff Accountant Securities and Exchange Commissi |
|
| September 27, 2011 | ||
| September 15, 2011 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida September 15, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief - Legal Securities and Exchange Commission 100 F Street, NE Washington |
|
| September 7, 2011 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida September 7, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief - Legal Securities and Exchange Commission 100 F Street, NE Washington, |
|
| August 24, 2011 |
August 23, 2011 Via E-mail Johnnie D. Johnson Chief Executive Officer and Chief Financial Officer Competitive Technologies, Inc. 777 Commerce Drive Fairfield, CT 06825 Re: Competitive Technologies, Inc. Form 10-K/A for the Fiscal Year Ended July 31, 2010 Filed July 21, 2011 Transition Report on Form 10-Q for the Transition Period from November 1, 2010 to December 31, 2010 Filed February 22, 2011 F |
|
| July 20, 2011 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida July 20, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief - Legal Securities and Exchange Commission 100 F Street, NE Washington, D.C |
|
| July 14, 2011 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida July 14, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief - Legal Securities and Exchange Commission 100 F Street, NE Washington, D.C |
|
| July 12, 2011 |
Letter to CUSIP for name change and reverse split (00011338.DOC;1) CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida July 12, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief - Legal Securities and Exchange Commission 100 F Street, NE Washington, D.C |
|
| June 28, 2011 |
CUTLER LAW GROUP M. Richard Cutler, Esq Corporate Securities Law M Gregory Cutler, Esq. Admitted in California & Texas Admitted in Florida June 28, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief - Legal Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4561 Re: Competitive Technologies, Inc. Form 10-K for the F |
|
| June 8, 2011 |
CUTLER LAW GROUP - M. RICHARD CUTLER, ESQ Corporate Securities Law M GREGORY CUTLER, ESQ. Admitted in California Admitted in Florida & Texas June 8, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Staff Attorney Mark P. Shuman, Branch Chief - Legal Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4561 Re: Competitive Technologies, Inc. Form 10-K for the |
|
| May 25, 2011 |
May 25, 2011 Via E-mail Johnnie D. Johnson Chief Executive Officer and Chief Financial Officer Competitive Technologies, Inc. 777 Commerce Drive Fairfield, CT 06825 Re: Competitive Technologies, Inc. Form 10-K for the Fiscal Year Ended July 31, 2010 Filed October 27, 2010 Form 10-K/A for the Fiscal Year Ended July 31, 2010 Filed March 4, 2011 Form 10-Q for the Quarterly Period Ended October 31, 20 |
|
| March 15, 2011 |
CUTLER LAW GROUP M. Richard Cutler, Esq.* Attorneys at Law M Gregory Cutler, Esq.** 3355 W. Alabama Ste. 1150 Houston, Texas 77098 *Admitted in California Tel (713) 888-0040 Fax (800) 836-0714 & Texas www.cutlerlaw.com **Admitted in Florida March 15, 2011 United States Securities and Exchange Commission Division of Enforcement c/o John D. Mitchell, Attorney 175 W. Jackson Blvd., Suite 900 Chicago, |
|
| March 4, 2011 |
CUTLER LAW GROUP Attorneys at Law M. Richard Cutler, Esq.* 3355 W. Alabama Ste. 1150 M Gregory Cutler, Esq.** Houston, Texas 77098 Tel (713) 888-0040 Fax (800) 836-0714 *Admitted in California & Texas www.cutlerlaw.com **Admitted in Florida ================================================================================ March 3, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, Sta |
|
| February 16, 2011 |
CUTLER LAW GROUP Attorneys at Law M. Richard Cutler, Esq.* 3355 W. Alabama Ste. 1150 M Gregory Cutler, Esq.** Houston, Texas 77098 Tel (713) 888-0040 Fax (800) 836-0714 *Admitted in California & Texas www.cutlerlaw.com **Admitted in Florida ================================================================================ February 16, 2011 Stephen Krikorian, Accounting Branch Chief Evan S. Jacobson, |
|
| February 2, 2011 |
February 2, 2011 Johnnie D. Johnson Chief Executive Officer and Chief Financial Officer Competitive Technologies, Inc. 777 Commerce Drive Fairfield, CT 06825 Re: Competitive Technologies, Inc. Form 10-K for the Fiscal Year Ended July 31, 2010 Form 10-Q for the Quarterly Period Ended October 31, 2010 Form 8-Ks Filed on September 13, 2010 and December 15, 2010 File No. 001-08696 Dear Mr. Johnson: We |
